TScan Therapeutics, Inc.
TCRX
$1.27
-$0.11-7.97%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 283.57% | -90.78% | -73.01% | -82.97% | -91.68% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 283.57% | -90.78% | -73.01% | -82.97% | -91.68% |
| Cost of Revenue | 19.84% | -16.35% | 15.48% | 26.62% | 14.13% |
| Gross Profit | -13.69% | 5.33% | -33.73% | -45.70% | -62.20% |
| SG&A Expenses | 21.90% | 30.20% | 25.70% | 19.02% | -8.82% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.29% | 30.84% | 17.59% | 24.83% | 8.10% |
| Operating Income | -15.55% | -71.90% | -31.82% | -38.62% | -37.95% |
| Income Before Tax | -13.22% | -82.58% | -29.96% | -31.67% | -33.59% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.22% | -82.58% | -29.96% | -31.67% | -33.59% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.22% | -82.58% | -29.96% | -31.67% | -33.59% |
| EBIT | -15.55% | -71.90% | -31.82% | -38.62% | -37.95% |
| EBITDA | -18.10% | -79.31% | -34.66% | -41.54% | -41.78% |
| EPS Basic | 58.17% | -54.30% | -16.49% | -17.44% | 32.45% |
| Normalized Basic EPS | 58.17% | -49.59% | -16.51% | -17.44% | 32.43% |
| EPS Diluted | 58.17% | -54.30% | -16.49% | -17.44% | 32.45% |
| Normalized Diluted EPS | 58.17% | -49.59% | -16.51% | -17.44% | 32.43% |
| Average Basic Shares Outstanding | 170.70% | 18.32% | 11.57% | 12.12% | 97.74% |
| Average Diluted Shares Outstanding | 170.70% | 18.32% | 11.57% | 12.12% | 97.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |